Inhibition of Hepatic Angiotensinogen Synthesis by an RNA Interference Therapeutic Agent: Implications for HTN and HF

Within the prior 24 months, I have had a financial relationship with a company producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients:

• Grant Support/Research Contract - Abbott; Alnylam; AstraZenca; Bayer AG; Novartis
• Consultant Fee/Honoraria/Speaker's Bureau - Abbott; Alnylam; AstraZenca; Bayer AG; Novartis; Axon Therapies; Avidity Biopharma; Merck/Schering Plough; Medpace; Parexel; Porter Health; Regeneron; River2Renal; Veristat; Verily; scPharmaceuticals; Zydus